openPR Logo
Press release

MEDIA ALERT for Saturday, October 1, 2011 Alzheimer's Association Long Island Hosts East End Walk to End Alzheimer's 2011

09-30-2011 08:21 AM CET | Associations & Organizations

Press release from: Alzheimer's Association Long Island

/ PR Agency: PRMG
WHO: Mary Ann Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Association Long Island
Cory Leible, Southampton resident who will walk from Southampton to East Hampton to raise funds for Alzheimer’s Association Long Island
Local elected officials
Participants in the East End Walk to End Alzheimer’s

WHAT: Eastern Long Island residents will unite in a movement to reclaim the future for millions at the Alzheimer’s Association’s Walk to End Alzheimer’s. The Walk will be preceded by a grand opening of the Southampton satellite office. The new office, outreach and support center will allow care consultants to schedule family meetings to provide information for families or individuals on the East End of Long Island who are coping with Alzheimer’s disease.

Alzheimer’s Association Long Island staff members and local elected officials will be joined by Cory Leible, a 70-year-old resident of Southampton who will be walking to raise awareness about Alzheimer’s disease and funds in support of the fight against Alzheimer’s. Mr. Leible has done this walk for the past six years and, this year, he has decided to dedicate the walk to fight Alzheimer’s. Mr. Leible will walk 30 miles from the Southampton office to Gurney’s Inn in Montauk. Teams and walkers will join Mr. Leible at the last 3.1 miles of the Walk.

Walk to End Alzheimer’s participants will be able to learn more about Alzheimer’s disease, advocacy opportunities, clinical trial enrollment, and support programs and services. Those who wish to donate can log on to www.2011eastendwtea.kintera.org/
longisland and click on the “Donate” link.

WHEN: Saturday, October 1, 2011
7:30 a.m. — Registration/Continental Breakfast/Grand Opening
8:00 a.m. — Mr. Leible begins his walk
3:00 p.m. — Walkers meet up with Mr. Leible at the East Hampton Nature Preserve and Beach sign to start the Walk to End Alzheimer’s
4:00 p.m. — Celebration BBQ at Gurney’s Inn

WHERE: START: Alzheimer’s Association Long Island Satellite Office
33 Flying Point Road, Suite 121/122
Southampton, NY

END: Gurney’s Inn
290 Old Montauk Highway
Montauk, NY

DIRECTIONS: From Sunrise Highway: Go east on Route 27. When going through Southampton Town, instead of bearing left to stay on Route 27, go straight as the road becomes Flying Point Road. Go 375 feet. Alzheimer’s Association Long Island is on the right-hand side.

PHOTO OPS: Ms. Malack-Ragona, Mr. Leible and elected officials cutting the ribbon during the grand opening. Mr. Leible beginning his walk. Teams and walkers joining Mr. Leible at the last 3.1 miles of the walk. Walkers arriving at Gurney’s Inn.

About the Alzheimer's Association:

The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.

Hank Russell, Public Relations Director
The Public Relations and Marketing Group
156 North Ocean Avenue
Patchogue, NY 11772
(631) 207-1057
hrussell@theprmg.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release MEDIA ALERT for Saturday, October 1, 2011 Alzheimer's Association Long Island Hosts East End Walk to End Alzheimer's 2011 here

News-ID: 194138 • Views:

More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as